[go: up one dir, main page]

ZA200205098B - Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. - Google Patents

Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.

Info

Publication number
ZA200205098B
ZA200205098B ZA200205098A ZA200205098A ZA200205098B ZA 200205098 B ZA200205098 B ZA 200205098B ZA 200205098 A ZA200205098 A ZA 200205098A ZA 200205098 A ZA200205098 A ZA 200205098A ZA 200205098 B ZA200205098 B ZA 200205098B
Authority
ZA
South Africa
Prior art keywords
dihydrobenzothiopyrans
dihydrobenzopyrans
tetrahydroquinolines
cox
treatment
Prior art date
Application number
ZA200205098A
Other languages
English (en)
Inventor
Jr Donald J Rogier
Jeffrey S Carter
John Jeffrey Talley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22635573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200205098(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ZA200205098B publication Critical patent/ZA200205098B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
ZA200205098A 2000-01-03 2002-06-25 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders. ZA200205098B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17428100P 2000-01-03 2000-01-03

Publications (1)

Publication Number Publication Date
ZA200205098B true ZA200205098B (en) 2004-03-31

Family

ID=22635573

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200205098A ZA200205098B (en) 2000-01-03 2002-06-25 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.

Country Status (16)

Country Link
US (2) US6822102B2 (xx)
EP (1) EP1274700B1 (xx)
JP (1) JP2003519221A (xx)
AR (1) AR026784A1 (xx)
AT (1) ATE282604T1 (xx)
AU (1) AU2584001A (xx)
CA (1) CA2395795A1 (xx)
DE (1) DE60016047T2 (xx)
EC (1) ECSP013867A (xx)
ES (1) ES2231301T3 (xx)
MX (1) MXPA02006617A (xx)
PE (1) PE20010995A1 (xx)
PT (1) PT1274700E (xx)
TW (1) TWI227234B (xx)
WO (1) WO2001049675A1 (xx)
ZA (1) ZA200205098B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
CA2424009A1 (en) 2003-03-28 2004-09-28 Ibm Canada Limited - Ibm Canada Limitee Context-sensitive attributes
GB0407908D0 (en) * 2004-04-07 2004-05-12 Univ York Ionic liquids
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006040672A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Substituted cyclopropyl chromene compounds for use in the treatment and prevention of inflammation related conditions
EP1861372A1 (en) 2005-02-24 2007-12-05 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症（ｐａｈ）および関連障害の治療のためのｉｐ受容体アゴニストとしての縮合ピロール
CN119954759B (zh) * 2025-01-03 2025-10-21 安炎达医药技术(广州)有限公司 一种苯并吡喃类cox-2抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3867997A (en) * 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE19638484A1 (de) * 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
ATE282604T1 (de) 2004-12-15
US6822102B2 (en) 2004-11-23
EP1274700B1 (en) 2004-11-17
PE20010995A1 (es) 2001-09-21
AU2584001A (en) 2001-07-16
ES2231301T3 (es) 2005-05-16
MXPA02006617A (es) 2004-09-10
DE60016047D1 (de) 2004-12-23
PT1274700E (pt) 2005-02-28
EP1274700A1 (en) 2003-01-15
ECSP013867A (es) 2002-09-27
US20050010050A1 (en) 2005-01-13
JP2003519221A (ja) 2003-06-17
TWI227234B (en) 2005-02-01
CA2395795A1 (en) 2001-07-12
DE60016047T2 (de) 2005-11-03
US20030232844A1 (en) 2003-12-18
WO2001049675A1 (en) 2001-07-12
AR026784A1 (es) 2003-02-26

Similar Documents

Publication Publication Date Title
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
AU2001228759A1 (en) Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
GB0007193D0 (en) Treatment of movrmrnt disorders
DE60223075D1 (en) Aberrometer
MXPA03007690A (es) Prenda absorbente y metodo para proporcionar la misma.
MXPA03003522A (es) Panal.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
MXPA03009167A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
IL161893A0 (en) 5-Phenylpyrimidines, agents comprising the same, method for production and use thereof
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
MXPA01001535A (es) Dispositivo para irradiacion untravioleta para el tratamiento de aguas residuales.
MXPA03002205A (es) Pentahidrato de gatifloxacina.
MXPA03009204A (es) PRODUCTO ABSORBENTE CON ADAPTACIoN MEJORADA.
PL369850A1 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
HUP0302065A3 (en) Chromanone derivatives, production and use thereof
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
MXPA01011720A (es) 3-piridil-4-arilpirroles sustituidos, y metodos terapeuticos y profilacticos relacionados.